ArticleNutrition & metabolism2025
Liver fibrosis increases the risk of subclinical atherosclerosis in patients with MASLD: a cross-sectional and longitudinal study.
Article in Nutrition & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Coronary atherosclerosis across stages of metabolic dysfunction-associated steatotic liver disease: a VCTE-CCTA study.Hepatology international · 2026Article
- Review
- The association between liver fibrosis markers and carotid atherosclerosis in non-alcoholic fatty liver disease is strongly influenced by age.BMC cardiovascular disorders · 2026Article
- Development and Validation of a Machine Learning-Based Prediction Model for Cardiovascular Disease in Patients with Metabolic Dysfunction-Associated Fatty Liver Disease.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2026Article
- Metabolic Dysfunction-Associated Steatotic Liver Disease and Liver Fibrosis are Associated with Advanced Cardiovascular-Kidney-Metabolic Syndrome in Chinese and US Populations.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThis study investigated the associations between both the progression and regression of liver fibrosis and subclinical atherosclerosis in patients withmetabolic dysfunction-associated steatotic liver disease (MASLD).
methodsWe conducted a cross-sectional analysis of 5,633MASLD participants who underwent transient elastography and carotid ultrasonography (Stage I). Additionally, a longitudinal study followed 2,670MASLD individuals without carotid atherosclerosis (CAS) at baseline, who underwent at least two health check-up examinations (Stage II). We used CAS and brachial ankle pulse wave velocity (baPWV) as markers of subclinical atherosclerosis and calculated the noninvasive fibrosis index FIB-4 to evaluate the probability of fibrosis.
resultsIn Stage I study, liver fibrosis was associated with increased CAS risk (OR = 1.17, 95%CI1.01-1.37, P = 0.045) and elevated baPWV (OR = 1.49, 95%CI 1.06-2.09, P = 0.022). In Stage II study, during a median of 24 months of follow-up, 466 (17.45%)MASLD patients developed CAS. Compared to patients with stable low probability, those who progressed to a high-intermediate probability of advanced fibrosis had a higher risk of incident CAS (HR = 1.89, 95%CI1.42-2.51, P < 0.001). In addition, persistent high-intermediate probability and regression to low probability of advanced fibrosis were associated with 2.32-fold (95%CI 1.86-2.89, P < 0.001) and 1.82-fold (95% 1.22-2.71, P = 0.004) increased risk of incident CAS, respectively. Moreover, persistent high-intermediate probability was independently correlated with elevated baPWV risk (HR = 3.17, 95%CI 1.76-5.71, P < 0.001).
conclusionsPersistent or progression to high-intermediate probability of fibrosis was associated with an increased risk of subclinical atherosclerosis, while regression to low probability of fibrosis does not significantly reduce this risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.